Alto Neuroscience, Inc. (ANRO)
$
2.69
-0.03 (-1.12%)
Key metrics
Financial statements
Free cash flow per share
-2.0286
Market cap
73.6 Million
Price to sales ratio
0
Debt to equity
0.0317
Current ratio
22.5331
Income quality
0.8388
Average inventory
0
ROE
-0.3978
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company focused on drug development in psychiatry. The company reported selling, general, and administrative expenses of $21,614,000.00 indicating its operational overhead costs. With total costs and expenses amounting to $0.00 the company reflects its overall spending. The EBITDA ratio is 0.00 highlighting the company's operational efficiency in managing its expenses against earnings. As it narrows its market focus, the company achieved a revenue of $0.00 illustrating its aim to cater to specific therapeutic needs. Furthermore, the company reported an income before tax of -$61,431,000.00 showcasing its pre-tax profitability as it works on developing treatments such as ALTO-100 for major depressive disorder (MDD) and post-traumatic stress disorder, ALTO-300, a melatonergic agonist and serotonergic antagonist, and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for cognitive impairment related to schizophrenia. Additionally, its innovative pipeline includes the development of ALTO-203, a histamine H3 receptor inverse agonist, and ALTO-202, an investigational antagonist of the GluN2B subunit of the NMDA receptor for MDD, alongside a unique AI-enabled biomarker platform. In the market context, the stock is affordable at $2.72 making it suitable for budget-conscious investors. The stock maintains an average trading volume of 304,861.00 indicating moderate liquidity for potential investors. With a market capitalization of $72,824,024.00 the company is classified as a small-cap player, which distinguishes it within the broader financial landscape. As a key player in the Biotechnology industry, Alto Neuroscience contributes significantly to the overall market landscape, showcasing its dedication to mental health advancements. Furthermore, it belongs to the Healthcare sector, driving innovation and growth as it seeks to address the complex challenges of psychiatric disorders through cutting-edge research and development.
Is Alto Neuroscience, Inc. (ANRO) a good investment?
Investing in Alto Neuroscience, Inc. (ANRO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Alto Neuroscience, Inc. (ANRO)'s stock forecast?
Analysts predict Alto Neuroscience, Inc. stock to fluctuate between $1.60 (low) and $17.55 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alto Neuroscience, Inc.'s market capitalization?
As of 2025-05-29, Alto Neuroscience, Inc.'s market cap is $72,824,024, based on 27,072,128 outstanding shares.
How does Alto Neuroscience, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Alto Neuroscience, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alto Neuroscience, Inc. (ANRO) stock?
To buy Alto Neuroscience, Inc. (ANRO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ANRO. Place an order (Market, Limit, etc.).
What is the best time to invest in Alto Neuroscience, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Alto Neuroscience, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$2.50 | Growth: 85.19%.
Where can I find Alto Neuroscience, Inc.'s investor relations reports?
Visit https://www.altoneuroscience.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alto Neuroscience, Inc.?
You can explore historical data from here
What is the all-time high and low for Alto Neuroscience, Inc. stock?
All-time high: $24 (2024-02-05) | All-time low: $1.60 (2025-04-04).
What are the key trends affecting Alto Neuroscience, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
a day ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, in Scottsdale, Arizona, held May 27-30, 2025. ALTO-300, also known as agomelatine, is an oral, small molecule designed to act as a melatonin agonist and 5-HT2C antagonist be.
businesswire.com
2 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in June: Jefferies Global Healthcare Conference, June 3-5th 2025: Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Thurs.
businesswire.com
16 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. “In the first quarter of 2025 we took important steps to deliver on our clinical and corporate objectives,” said Am.
businesswire.com
a month ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations at the Society of Biological Psychiatry (SOBP) Annual Meeting, in Toronto, Canada, held April 24-26, 2025. “The biological and clinical insights we presented at SOBP support our precision psychiatry pipeline and mark important advancements for.
businesswire.com
a month ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the JonesResearch Virtual CNS Day on Tuesday, April 29, 2025, at 12:30 pm ET and participate in one-on-one investor meetings. The presentation will be accessible via a live webcast on the Events and Presen.
businesswire.com
2 months ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full-year ended December 31, 2024, and highlighted recent progress across its pipeline of clinical-stage product candidates. “In 2024 we continued to advance our mission to change the way medicines are developed for neuropsychiatric conditio.
accessnewswire.com
3 months ago
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accessnewswire.com
3 months ago
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accessnewswire.com
3 months ago
LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accessnewswire.com
3 months ago
LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
See all news
